Not Just Yet.
In fact, most of my postings, particularly the ones anticipating marvelous futures for Anavex and the users of its to-be-approved drugs are open conjectures. Yes, should things resolve as I hope — with eventual FDA approval of either A2-73, or better, A3-71— I have solid-science reasons to believe my conjectures will eventually come to pass.
Presently, however, things Anavex are still rather nebulous, with no certain, clearly visible outcomes. Lots of postings here on executive remunerations, potential buy-outs or collaborations, patent validities and periods, and even (perplexingly) questions regarding the validity and applications of the clinical results posted at the CTAD conference.
For me, presently, all of the above (except for the CTAD presentation) is irrelevant. I’ve purchased my few AVXL shares, and will now just sit on them. Frankly, I don’t anticipate that anything substantive will happen until sometime into the next quarter, in Jan or Feb, at the earliest.
Yes, some official indication that one of the Anavex molecules will be released for use under “compassionate care” provisions, or an announcement of a favorable Big Pharma collaboration involving larger clinical trials and subsequent marketing and revenues projections will generate broader retail and institutional investment interest. Perhaps the share price might ascend toward $10 or so.
Nice, when that happens. Were I to sell at ten bucks, nice little profit for me, having gotten in under five bucks.
But instead of the daily or weekly perspectives that predominate here, I continue to look to the distant horizons for Anavex. As I’ve noted, I have a moderate neurodegenerative condition (hereditary spastic paraplegia, HSP) for which an Anavex drug has been shown in a transgenic rat study in France to eliminate symptoms. Some would claim my support of Anavex is overly based upon a personally hopeful application. Not really. I’m a biologist. I taught human physiology and know a reasonable amount about neurons, their organelles, and intrinsic chemistries.
More than most who post here, I comprehend the unique, revolutionary molecular biology of the Anavex molecules. I marvel how so many wish to compare (and degrade) Anavex technology with the dozens of previous Alzheimer’s clinical results; all failures. That’s easy (but ignorant). Billions have been spent by others, and not a one a success. Therefore (when lacking a knowledge of neuron chemistry and physiology), Anavex simply can’t and won’t be any different.
I (and the Anavex and Biogen and other Big Pharma insiders) know better. The Anavex stuff is entirely different. Nothing like it before. It requires new, open perspectives on nerve science. Until Anavex, what the Anavex molecules do inside neurons (and other cells, too); the restoration of “homeostasis,” the restoration of normalized cell functions; was pretty much thought to be impossible. Not even envisioned. But the murine lab data (rat and mouse studies) and the recent human results (as incomplete as they might be — I think they are entirely adequate) simply show that the Anavex molecules do work, with virtually no side effects.
Again, however, nothing useful is going to happen just yet. I await Anavex developments. It will take longer than I’d prefer; but the science is too good. It’ll happen.
